Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period

Benzion Beilin*, H. Bessler, L. Papismedov, M. Weinstock, Y. Shavit

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Background: Recently, new drugs and techniques for the treatment of postoperative pain were introduced, with the goal of enhancing opiates' analgesia while minimizing their side-effects. Cholinergic agents play an antinociceptive role, but their clinical use is quite limited, due to side-effects. Physostigmine is a cholinesterase inhibitor, which crosses the blood-brain barrier and elevates brain acetylcholine level. Physostigmine can produce analgesia by itself, and enhance opiate analgesia; but these effects are of short duration following bolus administration. Methods: We compared pain intensity and morphine consumption in two postoperative treatment groups: One group received continuous physostigmine infusion combined with morphine-based patient-controlled analgesia (PCA), and the other received PCA alone. Cholinergic anti-inflammatory pathways have recently been described. We therefore also compared changes in proinflammatory cytokine production in the two pain management groups. Results: Continuous infusion of physostigmine combined with morphine-based PCA in the postoperative period significantly reduced opiate consumption, and enhanced the analgesic response. Patients in the physostigmine group also exhibited reduced ex-vivo production of the proinflammatory cytokine, IL-1β. At the same time, physostigmine increased nausea and vomiting, mostly in the first 2h of the postoperative period. Conclusions: Physostigmine combined with morphine in the postoperative period reduced morphine consumption, enhanced analgesia, and attenuated production of the proinflammatory cytokine, IL-1β. This latter finding may account for the decreased pain observed in this group; this cytokine is known to mediate basal pain sensitivity and induce hyperalgesia in inflammatory conditions. Taking into account the other potential beneficial effects of physostigmine, we suggest that a continuous infusion of physostigmine should be considered as a useful component in multimodal postoperative analgesia.

Original languageEnglish
Pages (from-to)78-84
Number of pages7
JournalActa Anaesthesiologica Scandinavica
Volume49
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Keywords

  • Morphine consumption
  • Physostigmine
  • Postoperative pain
  • Proinflammatory cytokines

Fingerprint

Dive into the research topics of 'Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period'. Together they form a unique fingerprint.

Cite this